Will belumosudil be included in medical insurance in 2025 and interpretation of related policies

Belumosudil (Belumosudil), as an innovative small molecule kinase inhibitor, is mainly used to treat chronic graft-versus-host disease (cGVHD) and other diseases. As of2025, Besudil has been officially launched in China and has been included in the national medical insurance directory, which means that patients can reimburse part of the drug cost through medical insurance, which greatly reduces the treatment burden and improves the accessibility of the drug.

After Besudil is included in medical insurance, patients can purchase it at major formal medical institutions and pharmacies and enjoy the support of medical insurance reimbursement policies. The specific reimbursement ratio and amount vary depending on regional medical insurance policies. Patients need to consult the local hospital pharmacy for detailed information. Although the price is higher, the support of medical insurance makes the treatment of this innovative drug affordable for more patients.

Currently, the domestic market price of Besudil is about RMB 10,000 to RMB 20,000, making it a relatively expensive targeted therapy drug. In contrast, there are more affordable generic versions on the overseas market, priced at about 4,000 yuan, which provides an economic alternative for some patients, but the quality and sources of generic drugs need to be strictly screened.

With the continuous improvement of medical insurance policies and the acceleration of the approval of imported drugs, the popularity of besudil in the country is expected to further increase. When choosing medication, patients are advised to give priority to purchasing original drugs covered by medical insurance through formal channels to ensure medication safety and therapeutic effect. At the same time, we pay attention to policy trends, reasonably plan treatment budgets, and cooperate with doctors to formulate individualized treatment plans to improve the quality of disease management.

Reference materials:https://www.drugs.com/